Mangalam Drugs Promoter Group Releases Pledged Shares Worth 1,500 Units

1 min read     Updated on 10 Apr 2026, 10:19 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Shree Kishoriju Trading and Investments Private Limited released 1,500 pledged shares of Mangalam Drugs & Organics Limited on 06/02/2026, as disclosed to stock exchanges on 10/04/2026. The shares were previously encumbered with M/s Badjate Stock Broking Private Ltd as security for debt. Post-release, the promoter's total holding remains at 5,07,099 shares (3.20% of share capital) with no encumbered shares remaining.

powered bylight_fuzz_icon
37385391

*this image is generated using AI for illustrative purposes only.

Shree Kishoriju Trading and Investments Private Limited, a promoter group entity of Mangalam Drugs & Organics Limited, has released pledged shares from encumbrance in compliance with SEBI regulations. The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited on 10/04/2026.

Share Release Details

The promoter entity released 1,500 shares from pledge on 06/02/2026, which were previously encumbered as security for debt with M/s Badjate Stock Broking Private Ltd. This transaction represents a release of encumbrance rather than a sale or transfer of shares.

Parameter: Details
Release Date: 06/02/2026
Number of Shares Released: 1,500
Type of Encumbrance: Pledge
Beneficiary Entity: M/s Badjate Stock Broking Private Ltd
Purpose: Security for debt

Shareholding Impact

The release has resulted in a marginal change in the promoter's encumbered shareholding pattern. Shree Kishoriju Trading continues to hold 5,07,099 shares, representing 3.20% of Mangalam Drugs & Organics' total share capital.

Shareholding Details: Before Release After Release
Total Holding: 5,07,099 shares (3.20%) 5,07,099 shares (3.20%)
Encumbered Shares: 1,500 shares (0.00%) Nil
Free Shares: 5,05,599 shares 5,07,099 shares

Regulatory Compliance

The disclosure was made pursuant to Regulations 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The document was signed by Smita A. Dhoot, Director of Shree Kishoriju Trading and Investments Private Limited, bearing DIN 01867999.

Corporate Information

Shree Kishoriju Trading and Investments Private Limited operates under CIN U65990MH1981PTC024003 with its registered office located at Film Center, 2nd floor, unit no 21A, 68 Tardeo Road, Mumbai - 400034. The company maintains its promoter status in Mangalam Drugs & Organics Limited, which trades on both BSE (Scrip Code: 532637) and NSE (Symbol: MANGALAM).

Historical Stock Returns for Mangalam Drugs & Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-1.97%+6.06%-7.47%-54.80%-57.99%-73.26%

What factors enabled Shree Kishoriju Trading to repay the debt secured against these pledged shares to M/s Badjate Stock Broking?

Will this pledge release improve Mangalam Drugs & Organics' ability to raise capital or attract institutional investors?

Are there any remaining encumbrances on other promoter holdings that could be released in the near future?

Mangalam Drugs & Organics
View Company Insights
View All News
like16
dislike

Mangalam Drugs & Organics Limited Submits Compliance Certificate for Quarter Ended March 31, 2026

1 min read     Updated on 07 Apr 2026, 12:19 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Mangalam Drugs & Organics Limited submitted its compliance certificate under SEBI Depositories Regulations for the quarter ended March 31, 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper handling of securities dematerialisation processes during January-March 2026. The company communicated this regulatory compliance to BSE and NSE on April 06, 2026, demonstrating adherence to mandatory reporting requirements.

powered bylight_fuzz_icon
37046994

*this image is generated using AI for illustrative purposes only.

Mangalam drugs & organics Limited has submitted its quarterly compliance certificate under SEBI Depositories Regulations to stock exchanges. The pharmaceutical company filed the mandatory certificate for the quarter ended March 31, 2026, demonstrating adherence to regulatory requirements for securities handling and dematerialisation processes.

Regulatory Compliance Submission

The company submitted the compliance certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 on April 06, 2026. The certificate covers the period from January 01, 2026 to March 31, 2026, ensuring transparency in securities dematerialisation operations.

Parameter: Details
Reporting Period: January 01, 2026 to March 31, 2026
Submission Date: April 06, 2026
Regulation: SEBI Depositories Regulations 74(5)
Registrar: MUFG Intime India Private Limited

Certificate Confirmation Details

MUFG Intime India Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on April 3, 2026. The certificate confirms that securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to the depositories within prescribed timelines.

The registrar confirmed that all security certificates received for dematerialisation were appropriately verified, mutilated, and cancelled after due verification by depository participants. Additionally, the names of depositories were substituted in the register of members as registered owners following established procedures.

Stock Exchange Communication

The compliance certificate was formally communicated to both major Indian stock exchanges where the company's securities are listed. Managing Director Govardhan M. Dhoot signed the submission letter, requesting the exchanges to take the certificate on record as part of ongoing regulatory compliance.

Exchange: Details
BSE Limited: Scrip Code 532637
National Stock Exchange: Symbol MANGALAM
Signatory: Govardhan M. Dhoot, Managing Director
DIN: 01240086

The submission represents the company's commitment to maintaining regulatory compliance and transparency in securities operations, ensuring proper handling of investor securities through authorized depository participants and maintaining accurate records of ownership transfers.

Historical Stock Returns for Mangalam Drugs & Organics

1 Day5 Days1 Month6 Months1 Year5 Years
-1.97%+6.06%-7.47%-54.80%-57.99%-73.26%

Will Mangalam Drugs & Organics maintain consistent quarterly compliance submissions as regulatory scrutiny in the pharmaceutical sector intensifies?

How might the company's partnership with MUFG Intime India as registrar impact its future securities processing efficiency and investor relations?

What strategic initiatives is Mangalam Drugs planning for 2026 that could affect its stock performance on BSE and NSE?

Mangalam Drugs & Organics
View Company Insights
View All News
like19
dislike

More News on Mangalam Drugs & Organics

1 Year Returns:-57.99%